SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, today announced that Joe Bernardo has joined SeraCare's board of directors in the role of Chairman. Mr. Bernardo is also an Operating Partner at Linden Capital Partners who are the equity investors behind SeraCare Life Sciences. Prior to these roles, he served as the President of the Next-Generation Sequencing and Oncology division at Thermo Fisher Scientific.
Mr. Bernardo is a veteran diagnostics executive who spent over 25 years with premier diagnostics organizations such as Thermo Fisher Scientific, Siemens Healthcare, and Abbott Laboratories. He took on the role of President of the Next-Generation Sequencing and Oncology division in 2015 and was responsible for leading Thermo Fisher's efforts in these businesses, as well as his team which supported the development of innovative NGS-based solutions for other businesses within Thermo Fisher Scientific. Since 2008, Mr. Bernardo held four President positions with Thermo Fisher Scientific, including Next-Generation Sequencing, ImmunoDiagnostics (Phadia), Anatomic Pathology, and Fisher Healthcare. Prior to joining Thermo Fisher, Joe served as the Senior Vice President of the Central Lab Business Unit at Siemens Healthcare. Mr. Bernardo holds a Bachelor of Science in Chemistry from Lafayette College and a Master of Arts in Chemistry from the University of Virginia. He currently is a Senior Advisor to The Boston Consulting Group.
"SeraCare has a tremendous history supporting the growth and development of the IVD industry and with recent investments in the Clinical Genomics space, is experiencing rapid growth as that market expands," said Mr. Bernardo. He continued, "There is a desperate need for consistency in NGS as this technology continues to be adopted for clinical applications. SeraCare leads the market with scientifically proven controls and quality informatics to ensure NGS assay consistency."
"Joe has significant experience and brings an unparalleled knowledge base in the diagnostics arena," said Charlie Mamrak, CEO of SeraCare Life Sciences. "We are thrilled for him to join SeraCare as Chairman and to support SeraCare's continued growth strategy across our target IVD markets."
About SeraCare Life Sciences, Inc.
SeraCare enables the promise of precision medicine by advancing the understanding of disease and providing assurance of the diagnostic result. Our innovative tools and technologies not only provide assurance of the safe, effective, and accurate performance of diagnostic assays but also establish a framework for regulating, compiling, and interpreting data from precision diagnostics. Our portfolio includes a broad range of products such as quality control technologies, disease-state specimens and tissues for research and development, processed biological materials, and immunoassay reagents. For more information, please visit www.seracare.com and follow SeraCare on Twitter (@SeraCare).